We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 6,119

PTAB Denies Amgen’s IPR in Win for AbbVie - Article “Suggests a High Degree of Unpredictability” in the Art at Time of Invention
  • Banner & Witcoff Ltd
  • USA
  • February 4 2016

February 4, 2016 The Patent Trial and Appeal Board recently denied institution of Amgen’s inter partes review against an AbbVie patent covering


PTAB finds service of complaint was proper, denies IPR petitions filed one day too late
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • February 3 2016

The PTAB denied Lannett Holdings' petitions for IPR of AstraZeneca's U.S. Patent Nos. 6,750,237 and 7,220,767 because the petitions were filed one


Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


Roche Vs Cipla: Final leg of battle over Tarceva Patent
  • RNA, Intellectual Property Attorneys
  • India
  • February 2 2016

In the final leg of battle over Tarceva patent, Cipla has approached Supreme Court challenging High Court's Order holding it guilty of infringing


Hands Tied: Patenting Diagnostic Inventions Remain a Difficult Task
  • Bradley Arant Boult Cummings LLP
  • USA
  • February 2 2016

What does the Federal Circuit really think about the Supreme Court’s recent 101 jurisprudence? The denial of the petition for rehearing en banc in


Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


U.S. Biosimilar Litigation So Far
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • February 1 2016

The U.S. biosimilars statute, the Biologics Price Competition and Innovation Act (“BPCIA”), was enacted in 2010 as part of the Affordable Care Act


Patentability of human embryonic stem cells
  • Marks & Clerk
  • European Union
  • February 1 2016

The patentability of inventions relating to human embryonic stem cells (hESCs) has long been subject to uncertainty. A new potential change of


Revised Examination Guidelines and Revised Examination Handbook for Patent and Utility Model in Japan - applied to examination to be conducted on or after October 1, 2015
  • Yuasa and Hara
  • Japan
  • February 1 2016

On September 18, 2015, the Japan Patent Office published Revised Examination Guidelines for Patent and Utility Model in Japan (“Revised Examination


The implementation of the Nagoya Protocol in the EU
  • Taylor Wessing
  • European Union
  • January 31 2016

On 12 October 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization